TY - JOUR
T1 - Citrullinated and malondialdehyde-acetaldehyde-modified fibrinogen activates macrophages and promotes profibrotic responses in human lung fibroblasts
AU - Aripova, Nozima
AU - Duryee, Michael J.
AU - Zhou, Wenxian
AU - England, Bryant R.
AU - Hunter, Carlos D.
AU - Klingemann, Lauren E.
AU - Aripova, Nigina
AU - Nelson, Amy J.
AU - Katafiasz, Dawn
AU - Bailey, Kristina L.
AU - Poole, Jill A.
AU - Thiele, Geoffrey M.
AU - Mikuls, Ted R.
N1 - Publisher Copyright:
© 2025 American Physiological Society. All rights reserved.
PY - 2025/1
Y1 - 2025/1
N2 - The objective of this study was to assess fibrinogen (FIB) comodified with citrulline (CIT) and/or malondialdehyde-acetaldehyde (MAA) initiates macrophage-fibroblast interactions, leading to extracellular matrix (ECM) deposition that characterizes rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Macrophages (M/) were stimulated with native-FIB, FIB-CIT, FIB-MAA, or FIB-MAA-CIT. Supernatants (SNs) [M/-SN (U-937-derived) or M/P-SN (PBMC-derived)] or direct antigens were coincubated with human lung fibroblasts (HLFs). Gene expression was examined using RT-PCR. ECM deposition was quantified using immunohistochemistry and Western blot; cell signaling mechanisms were delineated. Platelet-derived growth factor (PDGF)-BB and TGF-b were measured in macrophage supernatants, and inhibition studies were performed using Su16f and SB431542, respectively. HLF gene expression of CD36, COL6A3, MMP-9, MMP-10, and MMP-12 was increased following stimulations with M/-SN generated from modified FIB but not from direct antigens. HLF stimulated with M/P-SNFIB-MAA-CIT derived from patients with RA-ILD resulted in 4- to 30-fold increases in COL6A3 and MMP12 expression; upregulation was greater in HLFs stimulated with M/P-SN derived from RA-ILD versus controls. HLF exposure to M/-SNFIB-MAA-CIT increased types I/VI collagen deposition versus all other M/-SN groups and was greater than FIB-MAA-CIT stimulation. PDGF-BB and TGF-b signaling had the highest concentrations identified in M/-SNFIB-MAA-CIT and M/P-SNFIB-MAA-CIT, particularly from RA-ILD-derived cells. PDGF-BB and TGF-b inhibitors, alone and in combination, significantly reduced HLF-mediated ECM deposition from M/-SN stimulations. These results show that comodified fibrinogen activates macrophages to produce PDGF-BB and TGF-b that promotes an aggressive HLF phenotype characterized by increased ECM deposition. These results suggest that targeting CIT and/or MAA modifications or downstream cellular signals could represent novel approaches to RA-ILD treatment. NEW & NOTEWORTHY This report demonstrates that fibrinogen simultaneously harboring two common posttranslational modifications activates macrophages to secrete platelet-derived growth factor (PDGF)-BB and transforming growth factor (TGF)-b. Resulting cross talk between activated macrophages and human lung fibroblasts leads to marked increases in extracellular matrix deposition. These protein modifications are abundant and colocalize in lung tissues from patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD), and the results suggest that agents targeting citrullination and/or malondialdehyde-acetaldehyde (MAA) adduct formation could represent novel therapeutic strategies.
AB - The objective of this study was to assess fibrinogen (FIB) comodified with citrulline (CIT) and/or malondialdehyde-acetaldehyde (MAA) initiates macrophage-fibroblast interactions, leading to extracellular matrix (ECM) deposition that characterizes rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Macrophages (M/) were stimulated with native-FIB, FIB-CIT, FIB-MAA, or FIB-MAA-CIT. Supernatants (SNs) [M/-SN (U-937-derived) or M/P-SN (PBMC-derived)] or direct antigens were coincubated with human lung fibroblasts (HLFs). Gene expression was examined using RT-PCR. ECM deposition was quantified using immunohistochemistry and Western blot; cell signaling mechanisms were delineated. Platelet-derived growth factor (PDGF)-BB and TGF-b were measured in macrophage supernatants, and inhibition studies were performed using Su16f and SB431542, respectively. HLF gene expression of CD36, COL6A3, MMP-9, MMP-10, and MMP-12 was increased following stimulations with M/-SN generated from modified FIB but not from direct antigens. HLF stimulated with M/P-SNFIB-MAA-CIT derived from patients with RA-ILD resulted in 4- to 30-fold increases in COL6A3 and MMP12 expression; upregulation was greater in HLFs stimulated with M/P-SN derived from RA-ILD versus controls. HLF exposure to M/-SNFIB-MAA-CIT increased types I/VI collagen deposition versus all other M/-SN groups and was greater than FIB-MAA-CIT stimulation. PDGF-BB and TGF-b signaling had the highest concentrations identified in M/-SNFIB-MAA-CIT and M/P-SNFIB-MAA-CIT, particularly from RA-ILD-derived cells. PDGF-BB and TGF-b inhibitors, alone and in combination, significantly reduced HLF-mediated ECM deposition from M/-SN stimulations. These results show that comodified fibrinogen activates macrophages to produce PDGF-BB and TGF-b that promotes an aggressive HLF phenotype characterized by increased ECM deposition. These results suggest that targeting CIT and/or MAA modifications or downstream cellular signals could represent novel approaches to RA-ILD treatment. NEW & NOTEWORTHY This report demonstrates that fibrinogen simultaneously harboring two common posttranslational modifications activates macrophages to secrete platelet-derived growth factor (PDGF)-BB and transforming growth factor (TGF)-b. Resulting cross talk between activated macrophages and human lung fibroblasts leads to marked increases in extracellular matrix deposition. These protein modifications are abundant and colocalize in lung tissues from patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD), and the results suggest that agents targeting citrullination and/or malondialdehyde-acetaldehyde (MAA) adduct formation could represent novel therapeutic strategies.
KW - citrullination
KW - malondialdehyde-acetaldehyde
KW - platelet-derived growth factor
KW - rheumatoid arthritis interstitial lung disease
KW - transforming growth factor beta
UR - http://www.scopus.com/inward/record.url?scp=85216108155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85216108155&partnerID=8YFLogxK
U2 - 10.1152/ajplung.00153.2024
DO - 10.1152/ajplung.00153.2024
M3 - Article
C2 - 39560968
AN - SCOPUS:85216108155
SN - 1040-0605
VL - 328
SP - L134-L147
JO - American Journal of Physiology - Lung Cellular and Molecular Physiology
JF - American Journal of Physiology - Lung Cellular and Molecular Physiology
IS - 1
ER -